The first patient, who was treated as first-line therapy for an ES (PD-L1+ on 40% of the tumor cells), presented a prolonged stable disease and stayed 12 months on therapy; the second patient with PD-L1+ (5% of tumor cells) anaplastic chordoma presented a shrinkage of some lesions and overall stable disease for 9 months on nivolumab; the last patient received pembrolizumab as first-line treatment for a MRT and presented a stable disease during 15 weeks. Here, CD274 is linked to neoplasm.